Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19: US Govt Gobbles Up 150 Million BinaxNOW Rapid Tests From Abbott

Executive Summary

Abbott will be paid $760m for the tests under a contract with the Department of Health and Human Services and the Department of Defense.

You may also be interested in...



US Government Awards $481M To Help Cue Health Expand COVID-19 Test Production

Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.

FDA Authorizes Abbott’s '$5, 15 Minute' COVID-19 Antigen Test

The BinaxNOW COVID-19 Ag Card portable lateral flow test, which delivers rapid results with no instrumentation, could be a “game changer” in the effort to reopen schools and other crowded places.

At Best, FDA Will Carry Out Only Half Of Domestic Surveillance Inspections In FY 2021, Report Says

A 5 May report from the US FDA says that even under the best COVID-19 conditions the agency’s inspections of makers of medical and tobacco products will likely be cut in half this year. The FDA also announced it will launch an agency-wide Inspectional Affairs Council to “plan and coordinate inspectional activities.”

Topics

UsernamePublicRestriction

Register

MT142650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel